Cochlear Ltd (COH) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of Cochlear Ltd stock A$203, price A$152, upside +32.9%, quality 71 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
The stock costs 25% less than our calculation considers fair.
Fair value A$202.51 · Undervalued
Quality 71/100
Low debt
Generates free cash flow
1.7% dividend yield · Sustainable
Upbeat coverage
Mixed Growth(revenue 5y +9.3 %/yr in AUD)
Thin margins · 6.3% net margin (TTM)
Mixed vs. peers(8/15)
Moderate moat60/100
Some data
Costs 64 times its yearly profit.
Changed on Oct 23: A$168.78→ A$202.51
Quality growth
Risks from the AI analysis
🚩Price drop: Earnings pressure and class action over prior guidance🚩Class action over prior guidance with earnings pressure🚩Rivals ahead on totally implantable implants🚩China volume-based procurement cuts prices
Watch Cochlear Ltd for free: we tell you when fair value or trend changes.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range A$89.13 – A$332.77 · fair‑value band A$141.36 – A$263.65 · the A$152.40 price screens below the A$202.51 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Cochlear in your weekly email
Every Wednesday you see whether Cochlear is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products.
Show moreShow less
It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories.
The company was founded in 1981 and is headquartered in Sydney, Australia.
Stock analysis
Cochlear Ltd (COH) currently trades at A$152.40, while our model-based Fair Value estimate is A$202.51, implying the stock looks roughly 25% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of A$97.96 per share, and 0 of the 26 models we run sit above the A$152.40 price.
Bear case: the Earnings-Based group reads lowest at A$34.90, and 26 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: A$141.36 (bear) to A$263.65 (bull), the price of A$152.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Cochlear Ltd reported revenue of A$2.3B in FY2026 versus A$1.6B in FY2022, a compound +9.2%/yr. Reported net income was A$147M in FY2026, compounding −15.5%/yr from FY2022.
Key figures
Market cap A$10.0B (≈ $6.9B) Mid · P/E ratio 64.3 · P/S ratio 4.25 · EPS (TTM) A$2.37 · Dividend yield 1.7% · Net margin 6.3% · Return on equity 8.0% · Return on assets (EBIT) 15.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 46% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at 33%, COH screens cheaper than that median.
Fair Value models
BearA$141.36Fair Value A$202.51BullA$263.65
Price A$152.40 · Upside +32.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFA$66.71A$114.91A$199.5578
Growth DCFA$67.26A$114.60A$198.9576
Residual IncomeA$23.14A$25.21A$29.4576
All 26 models by family
DCF Models
FCF DCFA$66.71A$114.91A$199.5578
Owner EarningsA$37.56A$63.75A$109.7474
5Y Revenue ExitA$50.96A$81.49A$121.4572
5Y EBITDA ExitA$63.75A$106.77A$158.9374
5Y P/E ExitA$46.14A$71.97A$100.0271
10Y Revenue ExitA$54.20A$84.86A$128.6266
10Y EBITDA ExitA$64.25A$103.53A$159.7267
10Y P/E ExitA$52.41A$77.83A$110.8564
Earnings-Based
Graham-DoddA$15.32A$60.65A$82.3864
Lynch FVA$15.01A$21.44A$27.8761
PEG = 1.0A$15.01A$21.44A$27.8757
EPVA$41.41A$48.36A$54.5874
Dividend Discount
Gordon GGMA$42.11A$93.81A$162.0565
DDM Multi-StageA$42.11A$75.92A$97.4766
Multiples
P/E MultipleA$37.16A$49.55A$61.9463
P/S MultipleA$28.72A$38.29A$47.8658
P/B MultipleA$64.88A$86.51A$108.1455
EV/EBITA$58.30A$77.86A$97.4266
EV/EBITDAA$64.96A$86.74A$108.5367
EV/RevenueA$41.50A$59.45A$77.4053
Asset-Based
NCAV (Graham)A$4.42A$6.69A$8.3754
Growth DCF
Growth DCFA$67.26A$114.60A$198.9576
Rev-Margin DCFA$50.96A$81.32A$118.7572
Economic Profit
Residual IncomeA$23.14A$25.21A$29.4576
ROIC CompounderA$45.86A$61.58A$82.9371
Growth Earnings
Growth-Adj P/EA$27.32A$39.03A$50.7467
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Start year 2021 (pandemic). Over 10 years: +7.5% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+0.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.6%
Dividend (yield on the price)1.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−13.6% vs −3.7%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 13%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +10.9% a year for the price and +1.2% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Cochlear's main strength is its extensive clinical data from over twenty years and one million patient hours supporting regulatory progress while its main weak point remains uncertainty from earnings pressure and a class action over prior guidance.
Main risk: MED-EL has launched the first commercial totally implantable cochlear implant in Europe while Cochlear remains in trials, which could allow rivals to capture market share or expand adoption ahead of Cochlear's own device.
Bull case: Cochlear could leverage its extensive clinical data and the upgradeable Nexa platform to accelerate its own totally implantable device and maintain leadership despite rivals' head start.
Bear case: If MED-EL and other rivals commercialize totally implantable systems faster and Chinese procurement sustains lower prices, Cochlear could lose share in key segments and face prolonged margin pressure.
Cochlear has accumulated more than twenty years of clinical data across three generations of fully implantable hearing devices, now exceeding one million patient hours in ongoing trials. This deep evidence base supports progress toward regulatory submissions, yet recent earnings pressure and a class action over prior guidance create uncertainty around near-term execution. Do the long-term insights from these studies outweigh the risks of slower adoption in the existing implant business?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+32.9% · Top 25%
Profitability
Return on equity (12 months)8.0% · Above median
Return on assets5.7% · Above median
Net margin (12 months)6.3% · Above median
Operating margin (12 months)14.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.8% · Below median
Dividend yield (12 months)1.7% · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)64.3× · Priciest 25%
P/B5.73× · Priciest 25%
P/S (12 months)4.25× · Pricier than median
Price / free cash flow (fiscal year)32.5× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cochlear Ltd Fair Value". https://www.fairvalue-calculator.com/stock/COH
Frequently asked questions
Is Cochlear Ltd (COH) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of A$202.51 versus a price of A$152.40, about +33% upside (undervalued).
What is the fair value of COH?
Our model-based fair value for Cochlear Ltd is A$202.51 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$152.40.
What is the quality score of COH?
Cochlear Ltd has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cochlear Ltd (COH)?
Our model-based price target is the fair value of A$202.51 (as of Nov 10, 2026) from 26 valuation models. Cautious scenario A$141.36, optimistic scenario A$263.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Cochlear Ltd stock forecast for 2026?
Our models put fair value at A$202.51, about +33% upside versus a price of A$152.40 (undervalued). Cautious scenario A$141.36, optimistic scenario A$263.65. The calculation is refreshed regularly with new filings.
What is the revenue of Cochlear Ltd (COH)?
Cochlear Ltd reported trailing-twelve-month revenue of about A$2.3B (latest available figure, as of Nov 10, 2026).
Does Cochlear Ltd pay a dividend?
Cochlear Ltd currently shows a dividend yield of 1.71% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Cochlear Ltd (COH) and when is the ex-dividend date?
Cochlear Ltd pays a dividend of A$2.60 per share a year, a dividend yield of 1.7%. The dividend was cut; the year before it was A$4.30 per share. The last ex-dividend date was Sep 21, 2026. A dividend has been paid every year since at least 1996. The payout ratio is 110% of earnings. Free cash flow covers the dividend 1.80 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Cochlear Ltd (COH)?
For today's price to be fair in a discounted-cash-flow model, Cochlear Ltd would have to grow free cash flow by +14.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.4 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of COH use?
Our models discount Cochlear Ltd at 8.3 %: a base by market capitalisation (mid), damped by beta 0.24, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cochlear Ltd that is +14.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Cochlear Ltd (COH) delivered so far?
Over the past 5 years revenue at Cochlear Ltd grew +9.4 % a year. The price currently implies free-cash-flow growth of +14.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cochlear Ltd (COH) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Cochlear Ltd (+14.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cochlear Ltd (COH)?
The free-cash-flow yield on the price is 3.08 %: that much free cash flow Cochlear Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cochlear Ltd (COH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cochlear Ltd it is A$202.51 per share (as of Nov 10, 2026), against a price of A$152.40. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Cochlear Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, COH trades below its calculated fair value: price A$152.40, fair value A$202.51, a gap of about +33% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COH?
No. The price is what the market pays today (A$152.40); the fair value is what the company's own numbers justify (A$202.51). For Cochlear Ltd the two are A$50.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cochlear Ltd worth?
The market values Cochlear Ltd at about A$10.0B (market capitalisation, as of Nov 10, 2026). Per share that is A$152.40; our models calculate a fair value of A$202.51 per share.
What do the bullish and bearish scenarios say about COH?
Our models span a range for Cochlear Ltd: cautious scenario A$141.36, base A$202.51, optimistic A$263.65 per share (as of Nov 10, 2026, price A$152.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of COH?
Cochlear Ltd trades at a price-to-earnings ratio of 64.3 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$202.51 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2026), reported earnings: 50.2. Other multiples: PEG 3.1, P/B 5.7, P/S 4.2, EV/EBITDA 20.4.
What is the PEG ratio of COH?
The PEG ratio of Cochlear Ltd is 3.08 (P/E divided by earnings growth, as of Nov 10, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Cochlear Ltd (COH)?
Balance-sheet figures for Cochlear Ltd (as of Nov 10, 2026): return on equity 8.0%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is COH from its 52-week high?
Cochlear Ltd trades at A$152.40, about 46% below its 52-week high of A$282.03 and 71% above the low of A$89.13 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of A$202.51 is for.
Which stocks are comparable to Cochlear Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cochlear Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$152.40, calculated fair value A$202.51 (+33%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COH calculated?
We run Cochlear Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$202.51 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Cochlear Ltd currently trades 25% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cochlear Ltd (COH)?
The closing price on Nov 10, 2026 was A$152.40. Our model-based fair value is A$202.51, about +33% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cochlear Ltd right now?
Solid quality (71/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (A$141.36 to A$263.65) leaves room in how you read the outcome.
Where does the earnings growth of Cochlear Ltd (COH) come from?
Earnings per share at Cochlear Ltd grew +3.8 % a year from 2015 to 2026. Broken into its drivers: revenue per share +6.9 %, EBIT margin −3.0 %, tax rate +0.1 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Cochlear Ltd
How large is the market capitalisation of Cochlear Ltd (COH)?
The market capitalisation of Cochlear Ltd is A$10.0B (≈ $6.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cochlear Ltd (COH)?
The price-to-sales ratio of Cochlear Ltd is 4.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cochlear Ltd (COH)?
Earnings per share at Cochlear Ltd are A$2.37 (price ÷ EPS = P/E 64.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cochlear Ltd (COH)?
The dividend yield of Cochlear Ltd is 1.7% (payout 110%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cochlear Ltd (COH)?
The net margin of Cochlear Ltd is 6.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cochlear Ltd (COH)?
The return on equity (ROE) of Cochlear Ltd is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cochlear Ltd (COH)?
On an EBIT basis the return on assets of Cochlear Ltd is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cochlear Ltd (COH)?
The operating margin of Cochlear Ltd is 14.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cochlear Ltd (COH)?
Revenue at Cochlear Ltd is growing +0.8% versus a year earlier (3y avg +6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cochlear Ltd (COH)?
Earnings per share at Cochlear Ltd are growing −21.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Cochlear Ltd (COH) carry?
The net debt of Cochlear Ltd is A$25.0M (fiscal year 2026, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cochlear Ltd in the live analysis
One click puts Cochlear Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 10, 2026